Regulatory Roundup: USP Hosts Symposium on Science and Standards - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: USP Hosts Symposium on Science and Standards


The US Pharmacopeia Convention (USP) held its first Science and Standards Symposium in Sao Paulo, Brazil, on August 23–24, 2012. The meeting focused on the importance of the Biopharmaceutics Classification System. Almost 300 regulators, academics, pharmaceutical manufacturers, and quality control experts from Latin American countries and the US attended the Symposium, which was cosponsored by the University of Sao Paulo.

According to a press release, Roger Williams, MD, chief executive officer of USP, closed the meeting by asking the attendees to think about a “global system of interchangeable products.” Williams stated, “If you have a highly soluble drug substance that is rapidly dissolving, it should be optimally bioavailable. Then, if you have two different products with the same active ingredients that are both optimally bioavailable, they should be bioequivalent.” According to release, “drug product monographs in the new USP Medicines Compendium, coupled with labeling, might advance the general approach for the classification and regulation of biopharmaceuticals.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here